Celldex Therapeutics Inc.
Common Stock · NASDAQ
Live TMS charts are coming soon.
Paper trading. Simulated, no real money.
No public theses on CLDX yet. When TMS traders open paper trades on it and make their thesis public, the long and short split, average conviction and hit rate show here.
Key stats load once market data is connected.
Celldex has discontinued its atopic dermatitis program after a clinical trial did not meet its goal, according to the headline. Holders should expect pipeline value to be reassessed following the setback.
Celldex reported that its Phase 2 atopic dermatitis study of barzolvolimab missed its primary and key secondary endpoints, and the company is discontinuing development in that indication. The drug showed a favorable safety profile in the study.
No SEC financials for CLDX yet. Companies that file 10-K and 10-Q reports show revenue, earnings, cash flow and the balance sheet here.
Source: SEC filings (10-K, 10-Q).
Paper trading only. Nothing here is financial advice.